Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 18% in the quarter, new products drive growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

3Q Revenues: $18.5 billion (+5%)

3Q Earnings: $4.7 billion (+59%)

YTD Revenues: $56.1 billion (+6%)

YTD Earnings: $13.8 billion (+34%)

Comments: Worldwide Pharmaceutical sales were $8.3 billion in the quarter, up 18%, with domestic sales up 33%, international sales up 3%, and a negative currency impact of 1%. Sales were driven by new products OLYSIO/SOVRIAD (simeprevir) for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; INVOKANA (canagliflozin) for type 2 diabetes; ZYTIGA (abiraterone acetate), for metastatic, castration-resistant prostate cancer; and IMBRUVICA (ibrutinib) for the treatment of several hematologic malignancies. Additional drivers were STELARA (+47% to $543 million), REMICADE (+5% to $1.8 billion), and INVEGA SUSTENNA/XEPLION (+24% to $403 million).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters